Prevalence  ||| S:0 E:11 ||| NNP
of  ||| S:11 E:14 ||| IN
skin  ||| S:14 E:19 ||| NN
tears  ||| S:19 E:25 ||| NNS
among  ||| S:25 E:31 ||| IN
hospitalized  ||| S:31 E:44 ||| JJ
patients  ||| S:44 E:53 ||| NNS
with  ||| S:53 E:58 ||| IN
cancer  ||| S:58 E:65 ||| NN
This  ||| S:65 E:70 ||| DT
study  ||| S:70 E:76 ||| NN
aimed  ||| S:76 E:82 ||| VBN
to  ||| S:82 E:85 ||| TO
analyze  ||| S:85 E:93 ||| VB
the  ||| S:93 E:97 ||| DT
prevalence  ||| S:97 E:108 ||| NN
of  ||| S:108 E:111 ||| IN
skin  ||| S:111 E:116 ||| NN
tears  ||| S:116 E:122 ||| NNS
( ||| S:122 E:123 ||| -LRB-
ST ||| S:123 E:125 ||| NNP
)  ||| S:125 E:127 ||| -RRB-
among  ||| S:127 E:133 ||| IN
hospitalized  ||| S:133 E:146 ||| JJ
oncology  ||| S:146 E:155 ||| JJ
patients  ||| S:155 E:164 ||| NNS
and  ||| S:164 E:168 ||| CC
associated  ||| S:168 E:179 ||| VBN
demographic  ||| S:179 E:191 ||| JJ
and  ||| S:191 E:195 ||| CC
clinical  ||| S:195 E:204 ||| JJ
variables ||| S:204 E:213 ||| NNS
.  ||| S:213 E:215 ||| .
This  ||| S:215 E:220 ||| DT
is  ||| S:220 E:223 ||| VBZ
an  ||| S:223 E:226 ||| DT
epidemiological  ||| S:226 E:242 ||| JJ
cross-sectional  ||| S:242 E:258 ||| JJ
study  ||| S:258 E:264 ||| NN
type ||| S:264 E:268 ||| NN
,  ||| S:268 E:270 ||| ,
performed  ||| S:270 E:280 ||| VBN
at  ||| S:280 E:283 ||| IN
Octavio  ||| S:283 E:291 ||| NNP
Frias  ||| S:291 E:297 ||| NNP
de  ||| S:297 E:300 ||| NNP
Oliveira  ||| S:300 E:309 ||| NNP
State  ||| S:309 E:315 ||| NNP
of  ||| S:315 E:318 ||| IN
SÃ£o  ||| S:318 E:322 ||| NNP
Paulo  ||| S:322 E:328 ||| NNP
Cancer  ||| S:328 E:335 ||| NNP
Institute ||| S:335 E:344 ||| NNP
.  ||| S:344 E:346 ||| .
All  ||| S:346 E:350 ||| DT
adult  ||| S:350 E:356 ||| NN
patients  ||| S:356 E:365 ||| NNS
hospitalized  ||| S:365 E:378 ||| VBN
from  ||| S:378 E:383 ||| IN
April  ||| S:383 E:389 ||| NNP
10th  ||| S:389 E:394 ||| JJ
to  ||| S:394 E:397 ||| TO
18th  ||| S:397 E:402 ||| CD
2010  ||| S:402 E:407 ||| CD
were  ||| S:407 E:412 ||| VBD
evaluated  ||| S:412 E:422 ||| VBN
by  ||| S:422 E:425 ||| IN
interview  ||| S:425 E:435 ||| NN
and  ||| S:435 E:439 ||| CC
physical  ||| S:439 E:448 ||| JJ
examination ||| S:448 E:459 ||| NN
.  ||| S:459 E:461 ||| .
Chi-square  ||| S:461 E:472 ||| JJ
test  ||| S:472 E:477 ||| NN
was  ||| S:477 E:481 ||| VBD
used  ||| S:481 E:486 ||| VBN
to  ||| S:486 E:489 ||| TO
compare  ||| S:489 E:497 ||| VB
demographic  ||| S:497 E:509 ||| JJ
and  ||| S:509 E:513 ||| CC
clinical  ||| S:513 E:522 ||| JJ
variables  ||| S:522 E:532 ||| NNS
between  ||| S:532 E:540 ||| IN
patients  ||| S:540 E:549 ||| NNS
with  ||| S:549 E:554 ||| IN
and  ||| S:554 E:558 ||| CC
without  ||| S:558 E:566 ||| IN
ST ||| S:566 E:568 ||| NNP
.  ||| S:568 E:570 ||| .
Five  ||| S:570 E:575 ||| CD
patients  ||| S:575 E:584 ||| NNS
among  ||| S:584 E:590 ||| IN
157  ||| S:590 E:594 ||| CD
had  ||| S:594 E:598 ||| VBD
nine  ||| S:598 E:603 ||| CD
skin  ||| S:603 E:608 ||| NN
tears ||| S:608 E:613 ||| NNS
,  ||| S:613 E:615 ||| ,
resulting  ||| S:615 E:625 ||| VBG
in  ||| S:625 E:628 ||| IN
a  ||| S:628 E:630 ||| DT
prevalence  ||| S:630 E:641 ||| NN
of  ||| S:641 E:644 ||| IN
3.3 ||| S:644 E:647 ||| CD
% ||| S:647 E:648 ||| NN
.  ||| S:648 E:650 ||| .
Among  ||| S:650 E:656 ||| IN
demographic  ||| S:656 E:668 ||| JJ
variables ||| S:668 E:677 ||| NNS
,  ||| S:677 E:679 ||| ,
only  ||| S:679 E:684 ||| JJ
number  ||| S:684 E:691 ||| NN
of  ||| S:691 E:694 ||| IN
children  ||| S:694 E:703 ||| NNS
showed  ||| S:703 E:710 ||| VBD
statistically  ||| S:710 E:724 ||| RB
significant  ||| S:724 E:736 ||| JJ
difference  ||| S:736 E:747 ||| NN
( ||| S:747 E:748 ||| -LRB-
p=0.027 ||| S:748 E:755 ||| NNP
)  ||| S:755 E:757 ||| -RRB-
between  ||| S:757 E:765 ||| IN
groups ||| S:765 E:771 ||| NNS
.  ||| S:771 E:773 ||| .
Clinically ||| S:773 E:783 ||| NNP
,  ||| S:783 E:785 ||| ,
patients  ||| S:785 E:794 ||| NNS
with  ||| S:794 E:799 ||| IN
ST  ||| S:799 E:802 ||| NNP
had  ||| S:802 E:806 ||| VBD
lower  ||| S:806 E:812 ||| RBR
Karnofsky  ||| S:812 E:822 ||| JJ
scores  ||| S:822 E:829 ||| NNS
( ||| S:829 E:830 ||| -LRB-
p=0.031 ||| S:830 E:837 ||| NNP
) ||| S:837 E:838 ||| -RRB-
,  ||| S:838 E:840 ||| ,
lower  ||| S:840 E:846 ||| JJR
scores  ||| S:846 E:853 ||| NNS
at  ||| S:853 E:856 ||| IN
Braden  ||| S:856 E:863 ||| NNP
Scale  ||| S:863 E:869 ||| NNP
( ||| S:869 E:870 ||| -LRB-
p=0.026 ||| S:870 E:877 ||| NNP
)  ||| S:877 E:879 ||| -RRB-
and  ||| S:879 E:883 ||| CC
less  ||| S:883 E:888 ||| RBR
collaborative  ||| S:888 E:902 ||| JJ
behaviors  ||| S:902 E:912 ||| NNS
( ||| S:912 E:913 ||| -LRB-
p=0.042 ||| S:913 E:920 ||| NNP
)  ||| S:920 E:922 ||| -RRB-
when  ||| S:922 E:927 ||| WRB
compared  ||| S:927 E:936 ||| VBN
to  ||| S:936 E:939 ||| TO
patients  ||| S:939 E:948 ||| NNS
with  ||| S:948 E:953 ||| IN
no  ||| S:953 E:956 ||| DT
lesions ||| S:956 E:963 ||| NN
.  ||| S:963 E:965 ||| .
This  ||| S:965 E:970 ||| DT
study  ||| S:970 E:976 ||| NN
contributes  ||| S:976 E:988 ||| VBZ
to  ||| S:988 E:991 ||| TO
a  ||| S:991 E:993 ||| DT
better  ||| S:993 E:1000 ||| JJR
knowledge  ||| S:1000 E:1010 ||| NN
of  ||| S:1010 E:1013 ||| IN
ST  ||| S:1013 E:1016 ||| NNP
in  ||| S:1016 E:1019 ||| IN
oncology  ||| S:1019 E:1028 ||| JJ
patients ||| S:1028 E:1036 ||| NNS
.  ||| S:1036 E:1038 ||| .
